Estamos realizando la búsqueda. Por favor, espere...
1582
37
170
29108
4409
2600
347
389
Abstract: Anti-tumour necrosis factor-alpha (TNF-[alfa) agents are effective drugs used in several chronic inflammatory diseases such as rheumatoid arthritis (RA). Psoriasiform lesions, including palmoplantar pustulosis, have been described following anti-TNF-a therapy. These lesions often resolve with topical therapy with or without discontinuation of these drugs. However, in some cases, psoriasiform lesions may persist despite anti-TNF-[alfa]withdrawal. We report on two RA patients treated with adalimumab (ADA) who developed palmoplantar pustular despite dermatological treatment and ADA discontinuation. Tocilizumab (TCZ) therapy was initiated because of persistence of skin lesions and flare of the disease. Following treatment with this drug, complete resolution of the dermatological lesions and induction of remission of RA was achieved. To the best of our knowledge, management of palmoplantar pustulosis due to TNF-[alfa] agents with TCZ leading to both improvement of the disease and resolution of the cutaneous lesions has not previously been reported.
Fuente: Joint, Bone, Spine: Revue du Rhumatisme, 2012, 79(5), 510-513
Editorial: Elsevier
Año de publicación: 2012
Nº de páginas: 4
Tipo de publicación: Artículo de Revista
DOI: 10.1016/j.jbspin.2012.06.010
ISSN: 1297-319X,1778-7254
Url de la publicación: https://doi.org/10.1016/j.jbspin.2012.06.010
Leer publicación
JAVIER RUEDA GOTOR
MIGUEL ANGEL GONZALEZ-GAY MANTECON
RICARDO BLANCO ALONSO
MARIA CARMEN GONZALEZ VELA
CRISTINA LOPEZ OBREGON
MARCOS ANTONIO GONZALEZ LOPEZ
Volver